Mumbai, Jan. 3 -- Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at Rs 78.47 crore, with EBITDA margin at 21.7% in Q2 FY26.
Total expenditure climbed 14.4% YoY to Rs 282.66 crore. Raw material costs declined 9.3% YoY to Rs 25.9 crore. Employee expenses rose 17.3% YoY to Rs 103 crore. Interest costs eased 32.8% YoY to Rs 1.93 crore, while depreciation inched up 1.7% YoY to Rs 9.2 crore.
On Half year basis, the company's consolidated net profit jumped 35.10% to Rs 98.52 crore on 16.92% jump in revenue from operations to Rs 707.67 crore in H1 FY26, compared with H1 FY25.
Nirav K. Mehta, MD and CEO, CORONA Remedies, sa...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.